Successful treatment of prolonged COVID-19 with Bamlanivimab in a patient with severe B-Cell aplasia due to treatment with an anti-CD20 monoclonal antibody: A case report

A 71-year-old female patient with B-cell depletion due to treatment with an anti-CD20 monoclonal antibody was admitted for worsening COVID-19. Overall, she had persistent viral shedding, worsening respiratory failure, and progressive pneumonia that did not improve despite dexamethasone and antibioti...

Descripción completa

Detalles Bibliográficos
Autores principales: Daher, Ayham, Müller, Tobias, Spiesshoefer, Jens, Dreher, Michael, Panse, Jens
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8628608/
https://www.ncbi.nlm.nih.gov/pubmed/34868871
http://dx.doi.org/10.1016/j.rmcr.2021.101560
_version_ 1784607031596941312
author Daher, Ayham
Müller, Tobias
Spiesshoefer, Jens
Dreher, Michael
Panse, Jens
author_facet Daher, Ayham
Müller, Tobias
Spiesshoefer, Jens
Dreher, Michael
Panse, Jens
author_sort Daher, Ayham
collection PubMed
description A 71-year-old female patient with B-cell depletion due to treatment with an anti-CD20 monoclonal antibody was admitted for worsening COVID-19. Overall, she had persistent viral shedding, worsening respiratory failure, and progressive pneumonia that did not improve despite dexamethasone and antibiotic therapy. After administration of bamlanivimab, a monoclonal antibody with high affinity for the receptor-binding domain of the SARS-CoV-2 spike protein, inflammatory markers rapidly decreased, SARS-CoV2 RT-PCR became negative, and the patient improved clinically and radiologically. In conclusion, we demonstrated successful treatment of prolonged COVID-19 in a patient with severe B-cell aplasia with a virus-neutralizing monoclonal antibody.
format Online
Article
Text
id pubmed-8628608
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-86286082021-11-29 Successful treatment of prolonged COVID-19 with Bamlanivimab in a patient with severe B-Cell aplasia due to treatment with an anti-CD20 monoclonal antibody: A case report Daher, Ayham Müller, Tobias Spiesshoefer, Jens Dreher, Michael Panse, Jens Respir Med Case Rep Case Report A 71-year-old female patient with B-cell depletion due to treatment with an anti-CD20 monoclonal antibody was admitted for worsening COVID-19. Overall, she had persistent viral shedding, worsening respiratory failure, and progressive pneumonia that did not improve despite dexamethasone and antibiotic therapy. After administration of bamlanivimab, a monoclonal antibody with high affinity for the receptor-binding domain of the SARS-CoV-2 spike protein, inflammatory markers rapidly decreased, SARS-CoV2 RT-PCR became negative, and the patient improved clinically and radiologically. In conclusion, we demonstrated successful treatment of prolonged COVID-19 in a patient with severe B-cell aplasia with a virus-neutralizing monoclonal antibody. Elsevier 2021-11-29 /pmc/articles/PMC8628608/ /pubmed/34868871 http://dx.doi.org/10.1016/j.rmcr.2021.101560 Text en © 2021 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Report
Daher, Ayham
Müller, Tobias
Spiesshoefer, Jens
Dreher, Michael
Panse, Jens
Successful treatment of prolonged COVID-19 with Bamlanivimab in a patient with severe B-Cell aplasia due to treatment with an anti-CD20 monoclonal antibody: A case report
title Successful treatment of prolonged COVID-19 with Bamlanivimab in a patient with severe B-Cell aplasia due to treatment with an anti-CD20 monoclonal antibody: A case report
title_full Successful treatment of prolonged COVID-19 with Bamlanivimab in a patient with severe B-Cell aplasia due to treatment with an anti-CD20 monoclonal antibody: A case report
title_fullStr Successful treatment of prolonged COVID-19 with Bamlanivimab in a patient with severe B-Cell aplasia due to treatment with an anti-CD20 monoclonal antibody: A case report
title_full_unstemmed Successful treatment of prolonged COVID-19 with Bamlanivimab in a patient with severe B-Cell aplasia due to treatment with an anti-CD20 monoclonal antibody: A case report
title_short Successful treatment of prolonged COVID-19 with Bamlanivimab in a patient with severe B-Cell aplasia due to treatment with an anti-CD20 monoclonal antibody: A case report
title_sort successful treatment of prolonged covid-19 with bamlanivimab in a patient with severe b-cell aplasia due to treatment with an anti-cd20 monoclonal antibody: a case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8628608/
https://www.ncbi.nlm.nih.gov/pubmed/34868871
http://dx.doi.org/10.1016/j.rmcr.2021.101560
work_keys_str_mv AT daherayham successfultreatmentofprolongedcovid19withbamlanivimabinapatientwithseverebcellaplasiaduetotreatmentwithananticd20monoclonalantibodyacasereport
AT mullertobias successfultreatmentofprolongedcovid19withbamlanivimabinapatientwithseverebcellaplasiaduetotreatmentwithananticd20monoclonalantibodyacasereport
AT spiesshoeferjens successfultreatmentofprolongedcovid19withbamlanivimabinapatientwithseverebcellaplasiaduetotreatmentwithananticd20monoclonalantibodyacasereport
AT drehermichael successfultreatmentofprolongedcovid19withbamlanivimabinapatientwithseverebcellaplasiaduetotreatmentwithananticd20monoclonalantibodyacasereport
AT pansejens successfultreatmentofprolongedcovid19withbamlanivimabinapatientwithseverebcellaplasiaduetotreatmentwithananticd20monoclonalantibodyacasereport

Ejemplares similares